Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension

Aim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antih...

Full description

Bibliographic Details
Main Authors: M. M. Beraya, V. V. Petriy, N. G. Sergushkina, V. I. Makolkin
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 1970-01-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1527
id doaj-9cf2989c7b894f8597469ce57a7334b1
record_format Article
spelling doaj-9cf2989c7b894f8597469ce57a7334b12021-07-28T13:50:39Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-015822281245Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertensionM. M. Beraya0V. V. Petriy1N. G. Sergushkina2V. I. Makolkin3I.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowI.M. Sechenov Moscow Medical Academy. MoscowAim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antihypertensive effect was insufficient. Results. Blood pressure (BP) normalized in 25,8% of the patients. Adding diuretics (hydrochlorthiazide, 25 mg/d, or Arifon® retard, 1,5 mg/d) normalized BP in the rest of the participants. Circadian BP rhythm was also normalized. Spirapril was well tolerated by the patients. Conclusion. ACE inhibitor spirapril (Quadropril®) effectively normalizes BP in patients with mild to moderate АП. In case of insufficient antihypertensive effect, combination with diuretics allows to normalize BP in extra 87% of the patients.https://cardiovascular.elpub.ru/jour/article/view/1527arterial hypertensionspiraprilcircadian blood pressure rhythmcombined therapy
collection DOAJ
language Russian
format Article
sources DOAJ
author M. M. Beraya
V. V. Petriy
N. G. Sergushkina
V. I. Makolkin
spellingShingle M. M. Beraya
V. V. Petriy
N. G. Sergushkina
V. I. Makolkin
Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
Кардиоваскулярная терапия и профилактика
arterial hypertension
spirapril
circadian blood pressure rhythm
combined therapy
author_facet M. M. Beraya
V. V. Petriy
N. G. Sergushkina
V. I. Makolkin
author_sort M. M. Beraya
title Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
title_short Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
title_full Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
title_fullStr Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
title_full_unstemmed Antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
title_sort antihypertensive spirapril effectiveness in patients with mild to moderate arterial hypertension
publisher «SILICEA-POLIGRAF» LLC
series Кардиоваскулярная терапия и профилактика
issn 1728-8800
2619-0125
publishDate 1970-01-01
description Aim. То study 12-week spirapril (Quadropril®) therapy effectiveness in patients with mild to moderate arterial hypertension (АП). Material and metliods. For 12 weeks, 62 patients with mild to moderate АП received spirapril (6 mg/d), with diuretics (hydrochlorthiazide or Arifon retard) added if antihypertensive effect was insufficient. Results. Blood pressure (BP) normalized in 25,8% of the patients. Adding diuretics (hydrochlorthiazide, 25 mg/d, or Arifon® retard, 1,5 mg/d) normalized BP in the rest of the participants. Circadian BP rhythm was also normalized. Spirapril was well tolerated by the patients. Conclusion. ACE inhibitor spirapril (Quadropril®) effectively normalizes BP in patients with mild to moderate АП. In case of insufficient antihypertensive effect, combination with diuretics allows to normalize BP in extra 87% of the patients.
topic arterial hypertension
spirapril
circadian blood pressure rhythm
combined therapy
url https://cardiovascular.elpub.ru/jour/article/view/1527
work_keys_str_mv AT mmberaya antihypertensivespiraprileffectivenessinpatientswithmildtomoderatearterialhypertension
AT vvpetriy antihypertensivespiraprileffectivenessinpatientswithmildtomoderatearterialhypertension
AT ngsergushkina antihypertensivespiraprileffectivenessinpatientswithmildtomoderatearterialhypertension
AT vimakolkin antihypertensivespiraprileffectivenessinpatientswithmildtomoderatearterialhypertension
_version_ 1721271483290877952